Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity
Circulation · 2026
DOI: 10.1161/circulationaha.125.077356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2026. Verfasst von Chang-Xiong Gong und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xinqiao Hospital, the Army Medical University, Chongqing, China (C.-X.G., P.-X.S., Y.-J.H., L.-L.H., X.-F.C., S.Z., M.-T.H.,…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, CD36 Antigens, Apolipoproteins D, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely understood, and effective treatments are lacking. Brain mural cells differ significantly from their peripheral counterparts, a distinction likely critical for maintaining BBB integrity. METHODS: We combined proteomic profiling of human brain vs peripheral mural cells with multiple ischemic stroke models (global apolipoprotein D [ApoD] knockout, mural cell–specific ApoD knockout, and adeno-associated virus–mediated ApoD overexpression) to evaluate the role of ApoD in BBB integrity. Mechanistic studies (co-immunoprecipitation, binding assays, including surface plasmon resonance, bio-layer interferometry, cross-linking mass spectrometry, and CD36 loss-of-function approaches, both in vitro and in vivo) were performed to determine how ApoD interacts with CD36 and inhibits its signaling. Finally, we assessed the effect of ApoD glycosylation on CD36 binding and tested therapeutic delivery of hypoglycosylated ApoD in stroke. RESULTS: Our study has shown an increased expression of ApoD in mural cells after ischemic stroke. We found that mural cell–derived ApoD functions as an inhibitory ligand of endothelial CD36, suppressing pathological endothelial proliferation, preserving BBB integrity, and promoting neurological recovery. Additionally, overexpression of ApoD in mural cells improved BBB integrity and enhanced functional recovery in ApoD -null mice. Mechanistically, ApoD competes with long-chain fatty acids for CD36 binding and directly attenuates downstream CD36 signaling. Furthermore, we reveal that peripheral hyperglycosylated ApoD (hyperglyco-ApoD) showed minimal effect on BBB integrity maintenance, whereas hypoglycosylation of ApoD enhances its binding affinity to CD36, amplifying its therapeutic efficacy. Exogenous administration of hypoglyco-ApoD via vein injection profoundly inhibited BBB disruption and improved neural function, especially in aging stroke. CONCLUSIONS: Our work identifies a previously unrecognized paracrine mechanism in which mural cell–derived ApoD directly engages endothelial CD36 to restrain pathological endothelial proliferation, thereby preserving BBB integrity and promoting neurological recovery after stroke. These findings further suggest that hypoglycosylated ApoD, with its higher CD36-binding affinity, merits investigation as a potential strategy to enhance BBB repair in central nervous system disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xinqiao Hospital, the Army Medical University, Chongqing, China (C.-X.G., P.-X.S., Y.-J.H., L.-L.H., X.-F.C., S.Z., M.-T.H., Z.-Y.M., Y.-L.F., B.-Q.W., Y.Z., W.-J.Z., F.-L.L., S.L., H.L., C.-H.Z…
- Chongqing Institute for Brain and Intelligence, Guangyang Bay Laboratory, Chongqing, China (C.-X.G., Q.-W.Y.).
- Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China (M.-T.H., J.-H.W., M.-Q.D.).
- Medical Care Center, Shigatse Branch of Xinqiao Hospital, the Army Medical University, Chongqing, China (C.-K.H.).
- Department of Neurology, Huaihai Hospital, Xuzhou medical University, Xuzhou, China (G.-Q.Y.).
- Department of Neurology, the 903rd Hospital of The Chinese People's Liberation Army. Hangzhou, China (Z.-M.Q.).
ORCID-Profile: Pei-Xia Shi, Yan-Jie Huang, Yue Dai, Lin-Lin Hu, Xiao-Feng Cheng, Meng-Ting He, Jian-Hua Wang, Yi-Liang Fang, Bin-Qiao Wang, Wen-Jie Zi, Zhong-Ming Qiu, Feng-Li Li, Sen Lin, Chen-Hao Zhao, Zhen-Yu Liu, Meng-Qiu Dong, Qin Ouyang, Hong-Ting Zheng, Jian-Qin Niu, Feng Mei, Qing-Wu Yang
Zitieren
APA
Gong, C. X., Shi, P. X., Huang, Y. J., Dai, Y., Hu, L. L., Cheng, X. F., Zhang, S., He, M. T., Wang, J. H., Meng, Z. Y., Fang, Y. L., Wang, B. Q., Zhao, Y., He, C. K., Yang, G. Q., Zi, W. J., Qiu, Z. M., Li, F. L., Lin, S., …, & Yang, Q. W. (2026). Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity. Circulation. https://doi.org/10.1161/circulationaha.125.077356
Vancouver
Gong CX, Shi PX, Huang YJ, Dai Y, Hu LL, Cheng XF, et al. Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity. Circulation. 2026. doi:10.1161/circulationaha.125.077356
BibTeX
@article{Gong2026,
author = {Gong, Chang-Xiong and Shi, Pei-Xia and Huang, Yan-Jie and Dai, Yue and Hu, Lin-Lin and Cheng, Xiao-Feng and Zhang, Shuang and He, Meng-Ting and Wang, Jian-Hua and Meng, Zhao-You and Fang, Yi-Liang and Wang, Bin-Qiao and Zhao, Yuan and He, Cheng-Kang and Yang, Guo-Qiang and Zi, Wen-Jie and Qiu, Zhong-Ming and Li, Feng-Li and Lin, Sen and Lu, Hui and Zhao, Chen-Hao and Zhang, Chi and Liu, Zhen-Yu and Dong, Meng-Qiu and Ouyang, Qin and Zheng, Hong-Ting and Niu, Jian-Qin and Mei, Feng and Sun, Bao-Liang and Zhou, Jin and Xie, Qi and Li, Fang-Fei and Yang, Qing-Wu},
title = {Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.125.077356}
}
EUVIMED